New hope for tough prostate cancer: drug shrinks PSA in many men
NCT ID NCT01171898
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 30 times
Summary
This study tested a new drug called ARN-509 in 127 men with advanced prostate cancer that had stopped responding to standard hormone therapy. The goal was to find a safe dose and see if the drug could lower PSA levels, a marker of cancer activity. The drug was given as a daily pill, and the study tracked how many men had a significant PSA drop after 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Study site
San Diego, California, United States
-
Study site
San Francisco, California, United States
-
Study site
Atlanta, Georgia, United States
-
Study site
Baltimore, Maryland, United States
-
Study site
Boston, Massachusetts, United States
-
Study site
Ann Arbor, Michigan, United States
-
Study site
Omaha, Nebraska, United States
-
Study site
New York, New York, United States
-
Study site
Raleigh, North Carolina, United States
-
Study site
Portland, Oregon, United States
-
Study site
Lancaster, Pennsylvania, United States
-
Study site
Myrtle Beach, South Carolina, United States
-
Study site
Dallas, Texas, United States
-
Study site
Seattle, Washington, United States
-
Study site
Madison, Wisconsin, United States
Conditions
Explore the condition pages connected to this study.